281 related articles for article (PubMed ID: 30415162)
21. Pathogenesis of and New Therapies for Hepatitis D.
Koh C; Heller T; Glenn JS
Gastroenterology; 2019 Jan; 156(2):461-476.e1. PubMed ID: 30342879
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic Strategies and New Intervention Points in Chronic Hepatitis Delta Virus Infection.
Guo Z; King T
Int J Mol Sci; 2015 Aug; 16(8):19537-52. PubMed ID: 26295228
[TBL] [Abstract][Full Text] [Related]
23. Hepatitis B Virus Therapeutic Agent ARB-1740 Has Inhibitory Effect on Hepatitis Delta Virus in a New Dually-Infected Humanized Mouse Model.
Ye X; Tateno C; Thi EP; Kakuni M; Snead NM; Ishida Y; Barnard TR; Sofia MJ; Shimada T; Lee ACH
ACS Infect Dis; 2019 May; 5(5):738-749. PubMed ID: 30408957
[TBL] [Abstract][Full Text] [Related]
24. Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIV-HBV-HDV-coinfected patients?
Sheldon J; Ramos B; Toro C; Ríos P; Martínez-Alarcón J; Bottecchia M; Romero M; Garcia-Samaniego J; Soriano V
Antivir Ther; 2008; 13(1):97-102. PubMed ID: 18389903
[TBL] [Abstract][Full Text] [Related]
25. Dynamics of in vivo hepatitis D virus infection.
Goyal A; Murray JM
J Theor Biol; 2016 Jun; 398():9-19. PubMed ID: 27012516
[TBL] [Abstract][Full Text] [Related]
26. A new HDV mouse model identifies mitochondrial antiviral signaling protein (MAVS) as a key player in IFN-β induction.
Suárez-Amarán L; Usai C; Di Scala M; Godoy C; Ni Y; Hommel M; Palomo L; Segura V; Olagüe C; Vales A; Ruiz-Ripa A; Buti M; Salido E; Prieto J; Urban S; Rodríguez-Frias F; Aldabe R; González-Aseguinolaza G
J Hepatol; 2017 Oct; 67(4):669-679. PubMed ID: 28527664
[TBL] [Abstract][Full Text] [Related]
27. Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies.
Allweiss L; Volmari A; Suri V; Wallin JJ; Flaherty JF; Manuilov D; Downie B; Lütgehetmann M; Bockmann JH; Urban S; Wedemeyer H; Dandri M
J Hepatol; 2024 Jun; 80(6):882-891. PubMed ID: 38340811
[TBL] [Abstract][Full Text] [Related]
28. Hepatitis delta virus: insights into a peculiar pathogen and novel treatment options.
Lempp FA; Ni Y; Urban S
Nat Rev Gastroenterol Hepatol; 2016 Oct; 13(10):580-9. PubMed ID: 27534692
[TBL] [Abstract][Full Text] [Related]
29. Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome.
Keskin O; Wedemeyer H; Tüzün A; Zachou K; Deda X; Dalekos GN; Heidrich B; Pehlivan S; Zeuzem S; Yalçın K; Gürel S; Tabak F; Idilman R; Bozkaya H; Manns M; Yurdaydin C
Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2342-49.e1-2. PubMed ID: 26044319
[TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Albrecht J; Schmid P; Le Gal F; Gordien E; Krawczyk A; Mijočević H; Karimzadeh H; Roggendorf M; Vaillant A
Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):877-889. PubMed ID: 28964701
[TBL] [Abstract][Full Text] [Related]
31. Hepatitis delta virus: From biological and medical aspects to current and investigational therapeutic options.
Alfaiate D; Dény P; Durantel D
Antiviral Res; 2015 Oct; 122():112-29. PubMed ID: 26275800
[TBL] [Abstract][Full Text] [Related]
32. [Hepatitis D virus: viral cycle and new therapeutic approaches].
Turon-Lagot V; Saviano A; Schuster C; Verrier ÉR
Virologie (Montrouge); 2019 Jun; 23(3):149-159. PubMed ID: 31210131
[TBL] [Abstract][Full Text] [Related]
33. Hepatitis delta virus.
Hughes SA; Wedemeyer H; Harrison PM
Lancet; 2011 Jul; 378(9785):73-85. PubMed ID: 21511329
[TBL] [Abstract][Full Text] [Related]
34. Current hepatitis delta virus type 1 (HDV1) infections in central and eastern Turkey indicate a wide genetic diversity that is probably linked to different HDV1 origins.
Le Gal F; Badur S; Hawajri NA; Akyüz F; Kaymakoglu S; Brichler S; Zoulim F; Gordien E; Gault E; Dény P
Arch Virol; 2012 Apr; 157(4):647-59. PubMed ID: 22241621
[TBL] [Abstract][Full Text] [Related]
35. Entecavir treatment of chronic hepatitis D.
Kabaçam G; Onder FO; Yakut M; Seven G; Karatayli SC; Karatayli E; Savas B; Idilman R; Bozdayi AM; Yurdaydin C
Clin Infect Dis; 2012 Sep; 55(5):645-50. PubMed ID: 22573857
[TBL] [Abstract][Full Text] [Related]
36. Hepatitis D revival.
Wedemeyer H
Liver Int; 2011 Jan; 31 Suppl 1():140-4. PubMed ID: 21205152
[TBL] [Abstract][Full Text] [Related]
37. Antiviral therapy of hepatitis delta virus infection - progress and challenges towards cure.
Wranke A; Wedemeyer H
Curr Opin Virol; 2016 Oct; 20():112-118. PubMed ID: 27792905
[TBL] [Abstract][Full Text] [Related]
38. Current management of delta hepatitis.
Rizzetto M
Liver Int; 2013 Feb; 33 Suppl 1():195-7. PubMed ID: 23286865
[TBL] [Abstract][Full Text] [Related]
39. The hepatitis delta virus: Replication and pathogenesis.
Sureau C; Negro F
J Hepatol; 2016 Apr; 64(1 Suppl):S102-S116. PubMed ID: 27084031
[TBL] [Abstract][Full Text] [Related]
40. [Hepatitis D: forgotten but not gone].
Moradpour D; Negro F
Rev Med Suisse; 2010 Sep; 6(261):1656-9. PubMed ID: 20939399
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
